Rivaroxaban, dabigatran and
apixaban are possibly associated
with a risk of hair loss (alopecia),
according to NZ’s Medsafe, which
has added these NOACs to its
medicines monitoring scheme for
the remainder of this year.
Hair loss is not a known side effect
of the NOACs but does occur with
heparin and warfarin, with Medsafe
saying the overall benefit-risk
balance of rivaroxaban, dabigatran
and apixaban remains positive.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.